TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03540303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR19 T cells carrying cytoplasmic activated PD-1
Description: step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Study: NCT02958358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT imaging, functional PET imaging
Description: Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
Study: NCT02211963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02474589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tecovirimat
Description: Study is based on Animal Regulatory Rule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Does not apply
Study: NCT03906292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg QD and asciminib 60 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Description: Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Description: Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg QD and asciminib 80 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD Monotherapy
Study: NCT04169672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Study: NCT01306721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00798174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard configuration vs. azygos coil
Description: Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
Study: NCT01395043

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placing bilateral TAP-catheters preoperatively
Description: Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters
Description: Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
Study: NCT02341144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-op percutaneous rectus sheath block
Description: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative rectus sheath block
Description: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT01073839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and Gemcitabine
Description: Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
Study: NCT02137538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Study: NCT00432835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Description: All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Description: All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
Study: NCT00883103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine jelly
Description: 2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plain aqueous gel
Description: Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Study: NCT02435771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 1- 400,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 1- 400,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 1- 400,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 2- 800,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 2- 800,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: Treatment 2- 800,000 IU
Study: NCT02304250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 1ml (5mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 1ml
Study: NCT01158430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT group therapy
Description: Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours
Study: NCT01677780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
Study: NCT00975572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 30 μg
Description: 440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg
Description: 440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
Description: 440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg
Description: 330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo control
Description: 110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
Study: NCT04532021

Intervention type: DIAGNOSTIC_TEST
Intervention: matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements
Description: These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements
Description: These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
Study: NCT02941393

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine pressure catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External tocodynamometry
Study: NCT01432535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN-2b (Sylatron®)
Description: Single 4.5 μg/kg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-2b (Sylatron®)
Description: Single 4.5 μg/kg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-2b (Sylatron®)
Description: Single 4.5 μg/kg dose
Study: NCT00313911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T
Description: 0.5 mL, Intramuscular (IM)
Study: NCT03714854

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
Study: NCT00313911

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib
Description: 0.5 mL, Intramuscular
Study: NCT00636792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
Study: NCT04107623

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: Using Q-ICG perfusion of the remaining Gastric Conduit will be compared

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
Study: NCT01574430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: 30% or 50% verteporfin dose PDT was given to patients with CSC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: 30% or 50% verteporfin dose PDT was given to patients with CSC
Study: NCT03009890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (Open Reduction Internal Fixation)
Description: Either volar of dorsal plating or both

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast treatment
Description: Hospitals may use their preferred protocol
Study: NCT00818415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium ER (BAYH6689)
Description: Extented release Naproxen sodium (660mg) administered once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Naproxen (Aleve, BAYH6689)
Description: Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
Study: NCT04367402

Intervention type: OTHER
Intervention: BioMedomics COVID-19 IgM-IgG Rapid Test
Description: Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus

Intervention type: OTHER
Intervention: BioMedomics COVID-19 IgM-IgG Rapid Test
Description: Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus

Intervention type: OTHER
Intervention: BioMedomics COVID-19 IgM-IgG Rapid Test
Description: Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
Study: NCT01231685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor
Description: Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor
Description: Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Study: NCT00847392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound prior to bladder catheterization
Description: Bedside ultrasound to estimated volume of urine in bladder
Study: NCT00835679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04512599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic Bar
Description: The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
Study: NCT00454818

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Saline; epicardial coronary artery infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion
Study: NCT00403650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
Study: NCT04495816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid Supplement
Description: Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo/Control
Description: Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
Study: NCT00215527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laronidase
Description: 0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
Study: NCT03506568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devers Drop Device (D3) app
Description: A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
Study: NCT01382225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic Solution, 0.18%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as run-in and placebo comparator
Study: NCT01702675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 50 mg
Description: ACH15 50mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 250 mg
Description: ACH15 250mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 500mg
Description: ACH15 500 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 - 1000mg
Description: ACH15 500mg capsule - two 500mg capsules in single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 - 2000mg
Description: ACH15 500mg capsule (four 500mg capsules in one dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 - 500mg
Description: ACH15 - 500mg twice a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 250 mg
Description: Capsule manufactured to mimic ACH15 250 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1000mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2000mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
Study: NCT04481191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq (V260)
Description: Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq (V260)
Description: Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: 0.5 mL dose IPV (Sabin strain based), administered via IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: 0.5 mL dose IPV (Sabin strain based), administered via IM injection